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Background: In vivo metastasis assays have traditionally been performed in mice, but the process is inefficient and
costly. However, since zebrafish do not develop an adaptive immune system until 14 days post-fertilization, human
cancer cells can survive and metastasize when transplanted into zebrafish larvae. Despite isolated reports, there has
been no systematic evaluation of the robustness of this system to date.
Methods: Individual cell lines were stained with CM-Dil and injected into the perivitelline space of 2-day old
zebrafish larvae. After 2-4 days fish were imaged using confocal microscopy and the number of metastatic cells was
determined using Fiji software.
Results: To determine whether zebrafish can faithfully report metastatic potential in human cancer cells, we
injected a series of cells with different metastatic potential into the perivitelline space of 2 day old embryos. Using
cells from breast, prostate, colon and pancreas we demonstrated that the degree of cell metastasis in fish is
proportional to their invasion potential in vitro. Highly metastatic cells such as MDA231, DU145, SW620 and ASPC-1
are seen in the vasculature and throughout the body of the fish after only 24–48 hours. Importantly, cells that are
not invasive in vitro such as T47D, LNCaP and HT29 do not metastasize in fish. Inactivation of JAK1/2 in
fibrosarcoma cells leads to loss of invasion in vitro and metastasis in vivo, and in zebrafish these cells show limited
spread throughout the zebrafish body compared with the highly metastatic parental cells. Further, knockdown of
WASF3 in DU145 cells which leads to loss of invasion in vitro and metastasis in vivo also results in suppression of
metastasis in zebrafish. In a cancer progression model involving normal MCF10A breast epithelial cells, the degree
of invasion/metastasis in vitro and in mice is mirrored in zebrafish. Using a modified version of Fiji software, it is
possible to quantify individual metastatic cells in the transparent larvae to correlate with invasion potential. We also
demonstrate, using lung cancers, that the zebrafish model can evaluate the metastatic ability of cancer cells
isolated from primary tumors.
Conclusions: The zebrafish model described here offers a rapid, robust, and inexpensive means of evaluating the
metastatic potential of human cancer cells. Using this model it is possible to critically evaluate whether genetic
manipulation of signaling pathways affects metastasis and whether primary tumors contain metastatic cells.
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Metastasis is the primary cause of human cancer mor-
tality, accounting for >90% of deaths due to cancer [1].
There is now abundant evidence that, independent of
the process of cellular transformation, the metastasis
phenotype is genetically controlled [2]. Metastasis is a
multistep process that involves local tumor invasion
followed by dissemination to, and re-establishment at,
distant sites. Families of genes have been described
which have no effect on cell proliferation but which can
suppress or promote metastasis [3,4]. Thus, targeting
metastasis may prove to be effective in reducing cancer
mortality if specific targets can be identified that sup-
press this phenotype. Here, we present a robust in vivo
system for rapidly and accurately evaluating the effec-
tiveness of candidate suppressor molecules.
Much of the analysis of metastasis pathways is con-
ducted in tightly controlled in vitro cell systems, usually
involving overexpression or ablation of a particular gene.
Assays such as wound healing, transwell motility, invasion
assays and hanging drop assays have been developed
which provide readouts of cellular phenotypes related to
metastasis [5-7]. These assays, however, do not address
the issue of intravasation of tumor cells into blood vessels
and extravasation into distant organs, a process requiring
an in vivo assay system. Typically, such assays are per-
formed in mice using experimental or spontaneous metas-
tasis models [8,9]. While it is ultimately necessary to
demonstrate that a pathway identified in vitro also affects
invasion and metastasis in vivo, mouse models have sig-
nificant drawbacks: 1) it is difficult to study early stages of
the process where it is necessary to rapidly evaluate
whether a particular drug or genetic manipulation has
affected the metastasis phenotype, 2) evaluating the
complete process in mice can require up to 6 months
(depending on the cell system), 3) these experiments are
expensive, immunosuppressed mice are required to study
human cells and per diem charges in barrier facilities are
costly, 4) in vivo imaging of small metastatic lesions is not
possible in the deep tissues of the mouse, thus typically
requiring termination and autopsy, thus extrapolation
across experimental populations to realize the result, 5)
popular immunosuppressed mice such as, nude (nu/nu),
the severe combined immunodeficiency (SCID), or mice
null for the recombination activating gene (Rag), have
residual immune competence, which can actually prevent
metastasis and, 6) the cohort size in these experiments is
often pragmatically limited by high costs, thus statistical
verification of metastasis modulation cannot be adequately
assessed when the effect is mild.
Zebrafish provide an experimentally and genetically
tractable animal model of a wide variety of human diseases
[10]. Recent studies have demonstrated that zebrafish form
spontaneous tumors with similar histopathological andgene expression profiles as human tumors [11-13]. The
zebrafish-cancer model overcomes the drawbacks of
murine xenograft models and offers alternative options
for studying human tumor angiogenesis and metastasis
[14-21]. Following early reports of the application of
zebrafish to evaluate metastasis [22], we now tested
whether metastasis in fish faithfully reports the metastatic
potential of a broad range of cancer cells. To do so, we
correlated in vitro invasion efficacy to in vivo metastasis
metrics following manipulation of the metastatic pheno-
type. Without exception, we show that gene manipulations
that affect in vitro invasion, alter metastasis in fish in a cor-
responding manner, demonstrating that the zebrafish is a
tractable model to assay metastatic potential of human
cancer cells. We also show that primary human cancer
cells can metastasize in fish and that this ability can be
used to predict metastatic potential in a clinical setting.
Results
The endogenous metastasis phenotype of human cancer
cells is maintained in zebrafish
We first investigated whether human cancer cells, with
known invasion/metastasis potential, could disseminate
throughout the zebrafish body. To minimize the possi-
bility that cells were introduced directly into the vascula-
ture in error during the injection process, the fish were
examined after 12 hours and those showing cells already
in the vasculature were removed from further analysis.
MDA-MB-231 breast cancer cells, for example, are
highly invasive in vitro and metastasize in experimental
and spontaneous murine models in vivo [8]. CM-Dil
stained MDA-MB-231 cells were injected into the
perivitelline cavity of 48 hours post fertilization (hpf )
embryos and analyzed at 30 hours post injection (hpi)
using confocal microscopy, where the spread of cancer
cells could be seen throughout the body of the fish. In
contrast, the T47D breast cancer cells, which do not typ-
ically invade or metastasize [7], did not show evidence
of metastasis in the fish (Figure 1a). In parallel, the inva-
sion potential of these cell lines was assessed in vitro
using standard transwell assays, which was concordant
with their ability to metastasize in the fish (Figure 1a).
During our analysis of non-metastatic cell lines (e.g.
T47D and (see below) HT29), we noted that, although
the majority of fish did not show any disseminated cells
within the fish body after the first 48 hour period, there
were infrequent cases where cells were detected in the
body of the fish. Quantitation of these cells revealed that
in these cases there were never more than 5 cells outside
the yolk sac region. We therefore set the cut off of >5
cells to indicate the definition of metastasis. Where
dissemination was seen for the highly metastatic cells,
however, there were significantly more than 5 cells
within the fish body.
Figure 1 Zebrafish faithfully report metastasis in human cancer cells. Confocal imaging (shown as z-stack images using 40 ×magnification)
shows that (a) metastatic MDA-MB-231 (MDA231) breast cancer cells (above) are dispersed throughout the fish body (arrows), whereas non-
invasive T47D cells (below) remain in the confines of the yolk sac. These results are mirrored by the Transwell invasion assays, shown in each case
to the right. Similarly (b) invasive DU145 prostate cancer cells show extensive spread throughout the fish compared with non-invasive LNCaP
cells which do not. In colon cancer cells (c), highly invasive SW620 cells metastasize extensively compared with non-invasive HT29 cells. Relative
invasion potential of pancreatic cancer cells (d) shows that more cells are distributed throughout the fish body for the relatively more invasive
AsPC-1 cells compared with less invasive BxPC3 cells. Assessment of fish showing metastasis (see text) in each experiment compared with the
invasion potential is shown in (e) showing the close correlation between relative invasion in vitro using the transwell assay and in vivo metastasis
in fish. ** P > 0.001; * P >0.05. Using the Tg(kdrl:EGFP) transgenic zebrafish (f), cancer cells (red) that have spread throughout the vasculature
(green) can be seen for MDA231 as show by successive imaging of 4 hours (200 ×magnification). The presence of MDA231 cells that have
extravasated into the body of the fish can clearly be seen (the white arrow tracks movement of a single cell and yellow arrow indicates
movement of another).
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cancer cells invade in vitro and metastasize in vivo in
mouse models [9] compared with LNCaP cells which do
not. As shown in Figure 1b, DU145 cells metastasize
throughout the body of the fish at 30 hpi but LNCaP
cells do not. The same correlation was seen for invasive
SW620 and non-invasive HT29 colon cancer cells
(Figure 1c), where again the correlation between inva-
sion and metastasis in the fish was observed. Finally we
studied the pancreatic ductal adenocarcinoma cells
AsPC-1 and BxPC3 (Figure 1d). In this case, the AsPC-1
cells showed higher invasion potential than BxPC3 inthe fish model which was consistent with in vitro
invasion assays (Figure 1d). The extent of metastasis in
fish for the highly invasive cells lines was readily appa-
rent with large numbers of cells throughout the body of
the fish (>25) after 24–48 hours. In contrast, the cells
with low metastatic potential rarely showed cells in the
body of the fish. These correlations were consistent
within the cohort of fish used for each experiment. To
evaluate the metastatic potential, therefore, we deter-
mined the number of fish that showed metastasis in the
four different cancer cell systems, compared with the
number that did not. In the highly invasive cell lines,
Figure 2 Metastasis of primary human lung tumor cells in
zebrafish. Cells derived from short term culture of a primary human
lung tumor with an undifferentiated phenotype (#8) show extensive
spread throughout the body of the fish (a, left) and invasion in vitro
(a, right). In contrast, cells from a well-differentiated adenocarcinoma
of the lung (#9) show only minimal dissemination in the fish and
limited invasion in vitro. From cohort studies (b), the number of fish
showing metastasis is significantly greater in #8 (shown as z-stack
images using 40 ×magnification). This relationship is maintained in
in vitro invasion assays (b, right).
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ASPC-1 (n = 57), metastasis was seen in 97%, 89%, 92%
and 84% of fish respectively (Figure 1e). In contrast, in
the poorly invasive cells, T47D (n = 64), LNCaP (n = 53),
HT29 (n = 84) and BxPC3 (n = 42) metastasis was seen
in only 9%, 15%, 14% and 26% of fish respectively
(Figure 1e). We then performed quantitative invasion
assays (see Methods) for all of these cell lines (Figure 1e)
where the relative proportion of invading cells mirrored
the distribution of metastasis in the in vivo fish model.
To demonstrate that cells from the perivitelline cavity
could intravasate into the circulation and extravasate
into the fish body, we used the Tg(kdrl:EGFP) transgenic
zebrafish which highlights the vasculature (Figure 1f ). In
this study, using invasive MDA231 cells, for example, we
could clearly see CM-Dil-labeled human cancer cells
both in the vasculature and in the body of the fish adja-
cent to the vasculature (Figure 1f ). This analysis demon-
strated that the human cancer cells showed the range of
phenotypes associated with metastasis. In contrast, the
non-invasive T47D cells, were never seen in the vascula-
ture of the host fish, nor in tissues distant from the
injection site (Figure 1a). Thus, these data suggest that
zebrafish can robustly report metastasis potential of dif-
ferent types of human cancer cells.
Assessment of the metastatic potential of primary human
cancer cells in zebrafish
In the experiments described above, we have demon-
strated that cancer cells with different in vitro invasion
phenotypes show a parallel metastasis phenotype in
zerbafish in all cases examined. These observations raised
the issue whether metastatic potential in primary human
cancer cells could also be assessed in this system. In a pilot
proof-of-principle study, therefore, we prepared primary
cultures of human lung cancer cells and maintained them
for 10–15 days to collect sufficient cells for injection. Cells
from only two different primary cultures were available to
us and these were injected into zebrafish as described
above and at 60 hpi tumor cell spread was assessed. The
cells from tumor #8 showed a clear dissemination in the
fish body, comparable with other highly invasive cell lines
described above (Figure 2a). On the other hand, the cells
from tumor #9 did not show any dissemination (Figure 2a).
Histopathology of the primary tumors in these two cases,
as part of routine diagnosis, showed that tumor #8 was
derived from an undifferentiated squamous cell carcin-
oma, whereas tumor #9 was a well-differentiated adeno-
carcinoma. Quantitation of metastasis as defined above
showed 81% (n = 42) of fish showed metastasis for cells
from tumor #8 compared with only 7% (n = 57) for cells
from tumor #9 (Figure 2b). Transwell invasion assays for
cells from these primary cultures demonstrated that
tumor #8 was highly invasive but that tumor #9 was not(Figure 2b). Thus, the relationship between invasion
in vitro and metastasis in vivo in zebrafish is maintained
in this analysis. Taken together, our data suggest that
zebrafish may be a reliable in vivo model for assessment
of the metastatic potential of primary human cancer
cells.
The genetic regulation of tumor metastasis is maintained
in zebrafish
WASF3 (or WAVE3) is a member of the Wiskott-Aldrich
syndrome protein family. The structural motifs in the
WASF3 protein predict that it orchestrates the reor-
ganization of the actin cytoskeleton, which leads to the
development of invadapodia and lamellipodia which
facilitate invasion [4,23]. We have previously shown that
WASF3 is high expressed in primary human cancer and
fundamentally important for metastatic spread of cancer
cells [7-9,24,25]. To relate metastasis in fish with metas-
tasis in mice, we analyzed DU145 cells in both models.
As shown in Figure 3a-b, the control DU145 cells
(shGFP) which have high WASF3 expression levels were
highly invasive in vitro. Consistently, the control DU145
cells (shGFP) showed metastasis in the fish model at 60
hpi, whereas the stable WASF3-deficient cells (shW3-1
and shW3-2) show significantly reduced metastasis
(Figure 3c). Quantitation of metastasis as defined above
showed 94% (n = 51) of fish showed metastasis for
control cells (shGFP) compared with only 12% (n = 72,
shW3-1) and 18% (n = 66, shW3-2) for WASF3 knockdown
Figure 3 Comparable WASF3-induced metastasis of DU145 cells in mice and fish. Knockdown of WASF3 in DU145 cells using two different
shRNA constructs (shW3-1 and shW3-2) shows significant reduction in protein levels (a). DU145 cells transfected with a control shRNA (shGFP)
show high level invasion in vitro (b) but knockdown of WASF3 in these cells using two different shRNAs (shW3-1 and shW3-2) leads to
significantly reduced invasion. In fish (c), no, or reduced numbers, of WASF3 knockdown cells (shW3-1 and shW3-2) spread throughout the body
of the fish, whereas the control cells (shGFP) spread extensively (arrows) (shown as z-stack images using 40 ×magnification). Quantitation of
invasion potential shows a significant reduction (** p >0.001) in the WASF3 knockdown cells compared with control shGFP cells (d, above). This
reduced invasion is mirrored by the metastasis efficiency in cohort studies of fish (d, below). In mice (e), tumor nodules (arrows) on the surface of
the lungs can be seen in the control shRNA treated cells compared with cells expressing shW3-1 (left) 3 months after tail veil injection.
Histological examination of the lungs of these mice shows large tumor foci from the control cells (arrows) compared with small tumor foci for
the WASF3 knockdown cells.
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(Figure 3e), lung surface tumors and large tumor foci
throughout the lungs were seen after 3 months, while
the WASF3 knockdown cells clearly showed a significant
reduction in both invasion potential or metastasis capa-
bility (no detectable tumors on the lung surface and very
small tumor foci throughout the lung). Thus, assays eva-
luating metastatic potential of cells are consistent between
mouse and zebrafish.
Quantitation of metastasis in zebrafish using Fiji
algorithms
The transparent zebrafish embryos make imaging meta-
static cells relatively straightforward using both con-
ventional and confocal microscopy. Fish can be lightly
anesthetized and photographed allowing repeat analysis
of the same fish after different time intervals. Althoughthe experiments described above show a clear distinction
between the ability to metastasize and not, in certain
circumstance it may be necessary to quantify the meta-
static potential. To achieve this is a realistic time frame,
we have modified the open source Fiji software [26]
to quantitate the number of cells that have left the
perivitelline space as a measure of metastasis. The pho-
tographs of the fish are used in this analysis and an
example is shown in Figure 4a. In this system, the
CM-Dil stained cells are imaged and counted through-
out the fish. The cells remaining in the yolk sac are
masked off and eliminated, and the number of cells in
the fish body used as an estimate of the metastatic cap-
ability of the cells. In the example shown in Figure 4,
MDA231 cells were imaged at 48 hpi in 10 different fish.
The same fish were then imaged at 80 hpi (Figure 4b),
where there was no significant difference in the number
Figure 4 Quantitation of metastatic cells in zebrafish using Fiji. Fluorescent (a, left) and bright field (a, center) images of Dil-stained (red)
human MDA231 cancer cells are captured by confocal microscopy. Individual red cells are counted relative to their location throughout the fish
(a, center) using Fiji. Cells within the yolk sac (boxed) can be eliminated from the cell count (a, right). Cells were counted using this approach
(b) either throughout the body of the fish (left) or confined to the tail region (right) in the same fish over a 48–120 hours period after injection.
Cells visualized by the fluorescent dye (arrows) and following Fiji analysis (right) were plotted from the same 10 different fish at the three time
points showing (c) no significant difference in mean number of cells counted in the whole fish body (left) up to 80 hours. Although the number
of metastatic cells was reduced when cells restricted to the tail region were counted (right), there was again no significant difference in
metastatic cells up to 80 hours after injection. At later stages (120 hpi), an ~25% reduction in metastatic cell numbers was observed in both the
fish body and the tail alone. Data are presented as the mean of three independent experiments (n = 3) ± SEM, P < 0.05.
Teng et al. BMC Cancer 2013, 13:453 Page 6 of 12
http://www.biomedcentral.com/1471-2407/13/453of metastatic cells (Figure 4c, left). At 120 hpi, however,
there was a significant decline in the number of cells
(Figure 4b-c). To streamline the study, we repeated the
analysis where we counted only cells in the tail region,
distal to the yolk sac (Figure 4b, right). Again, we saw no
difference in the metastatic spread of the cells during
early stages but saw a reduced number of cells at 120
hpi (Figure 4c, right). This analysis has advantages in
that there is no need to assess the number of cells that
remained in the yolk sac region or that had metastasized
to the head region where the large area occupied by the
eye presents challenges in quantitation.Zebrafish show variation in metastasis potential related
to tumor cell progression
To further evaluate the relationship between in vivo cell
metastasis in zebrafish and in vitro cell invasion through
matrigel, we studied the MCF10A system described by
Tang et al. [27] where HRAS oncogene transformation
and in vivo selection identified cells that have undergone
progressive development into highly metastatic cells.
The parental MCF10A cells (M-I), which originated
from normal breast epithelial cells have been immorta-
lized, but not transformed, and these cells do not
metastasize in fish at 60 and 120 hpi (Figure 5a-b).
Figure 5 Relative metastatic potential in human cancer cells during progression from low to high grade tumors. When immortal,
non-transformed MCF10A cells (M-I) were introduced into the zebrafish metastasis model (a), no spread was seen in any of the fish analyzed at
60 hpi. The cells (M-II) recovered from low grade hyperplastic lesions in mice from MCF10AT cells (MCF10A cells transformed with activated
HRAS) show increased metastatic potential (arrows). M-III cells, which were derived from well differentiated carcinomas derived from M-II cells,
show reduced metastatic potential, whereas M-IV cells, recovered from aggressive adenocarcinomas derived from M-II cells, show enhanced
metastatic potential. The same relationship was seen at 120 hpi (b) (shown as z-stack images using 40× magnification). Quantitation of metastatic
cells throughout the fish body using Fiji (c) confirms the relationship between tumor grade and metastatic potential in fish (left). At 120 hpi,
although the relative proportion of metastatic cells is seen in the M-II/M-III/M-IV comparison, the overall number of cells in each tumor grade was
reduced. When the same comparison was performed using the in vitro invasion assay (d), the relative proportion of invading cells in the different
sub groups was again maintained. Data are presented as the mean of three independent experiments (n = 3) ± SEM, **P < 0.01.
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was expressed, are described as oncogenically initiated
MCF10AT cells [28]. These cells were then passaged
through mice (M-II) and can form simple ducts that can
progress to benign hyperplastic lesion and occasionally
carcinomas. When M-II cells were challenged in the
zebrafish assay, they showed modest spread in the fish
body (Figure 5a-b). Cells (M-III) that were selected from
one of the carcinomas that arose from the M-II cells pre-
dominantly form well differentiated carcinomas in mice.
When these cells were introduced into the zebrafish
model, their low grade phenotype is reflected in the poor
ability to metastasis (Figure 5a-b). During the develop-
ment of these low grade tumors, however, variants arose
that were more aggressive, formed carcinomas and had
acquired a metastatic phenotype in mice. When these cells
(M-IV) were injected into the fish model, they showed
the highest level of metastasis (Figure 5a-b). We nextquantified the metastatic cells in the tail region using
Fiji as described above. Twelve fish per group were moni-
tored and confocal images were taken at 60 and 120 hpi,
respectively. Quantitative analysis showed that relative
metastatic ability of these cells in fish was defined as
M-IV >M-II >M-III >M-I (Figure 5c), which is consistent
with findings from in vitro invasion assays (Figure 5d).
Overall, therefore, in this progression model of human
cancer cells, the zebrafish model accurately reports the
relative level of metastatic potential in the different cells.
Suppression of oncogenic kinases affects metastasis in
zebrafish
One important application of a rapid and robust in vivo
metastasis assay is the ability to quickly evaluate whether
a particular genetic manipulation in cancer cells leads to
loss of metastatic potential. JAK1 and JAK2, for example,
have been implicated in promoting invasion and metastasis
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cells, which are highly invasive (Figure 6a). When wild-
type 2C4 cells were injected into zebrafish, they show
metastasis after 24 hours, which is sustained over a 5 day
period (Figure 6b). The derivative U4C cells, which are
genetically deficient for JAK1 [29,30], failed to spread
throughout the fish body and showed virtually no invasion
in vitro (Figure 6a). In fact, not a single cell was seen in
the fish body, but sustained cell masses were seen in the
perivitelline space demonstrating the persistence of viable
cells in the fish over this period. In the derivative JAK2-
deficient γ2A fibrosacrcoma cells [31,32], low-level metas-
tasis was still seen but significantly suppressed compared
with wild-type 2C4 cells (Figure 6b). Again, the quantita-
tion analysis using Fiji algorithms showed the relative
metastasis potential of these three different cell lines in
the zebrafish reflected in vitro invasion assays (Figure 6c).Figure 6 Suppression of invasion in vitro leads to suppression
of metastasis in zebrafish following loss of JAK1 or JAK2
expression. Western blot analysis confirmed JAK-deficiencies in U4C
and γ 2A cells (a). When human 2C4 fibrosarcoma cells are injected
into zebrafish (b, left) (shown as z-stack images using 40×
magnification), extensive spread throughout the body of the fish
can be seen over 120 hpi. This metastasis potential correlates with
in vitro invasion (b, right). In both JAK1-deficient U4C cells and
JAK2-deficient γ2A cells, reduced levels of metastatic spread are seen
(c, left), which correlates with reduced invasion in vitro (c, right).Discussion
Dissection of the functional aspects of genes that impact
the metastasis phenotype requires a robust assay for
tumor spread. While it is accepted that, in the final ana-
lysis, rodent models should be used to evaluate metasta-
sis, this approach is costly and inefficient as an up-front
assay to determine whether a particular genetic manipu-
lation affects the metastasis phenotype. The spontaneous
metastasis assay [8,9] has shortcomings, since it cannot
be used to evaluate intravasation into the blood vessels.
The zebrafish model, on the other hand provides a solu-
tion to the time-consuming and costly mouse experi-
ments, since in many cases the assay can be performed
within 24–36 hours of xenotransplantation, in large
cohorts of fish, providing statistical power to the results.
Although we have only studied cancer cells from breast,
pancreas, colon and sarcomas thus far, in all cases
in vitro invasion ability correlated with the metastatic
potential of tumor cells to spread in vivo. Importantly,
we have shown that genetic manipulations of human
cancer cells which affect invasion, also affect metastasis
in fish. Although the technical dexterity needed to inject
48 hpf zebrafish can be demanding, the absence of an
adaptive immune response for the first 14 days post
fertilization (dpf ) [33] avoids side effects and dosing
issues related to using immunosuppressants [34,35].
Early studies targeting the yolk sac as a site of injection
truly challenged cancer cells to enter the blood stream.
The blood supply to the yolk sac is extensive since this
sustains the fish for the first 5 dpf and maximizes the
opportunity for intravasation. It has been shown using
the cloche mutant fish, which do not develop a vascula-
ture or circulation, that metastatic human cells injected
into the yolk sac cannot metastasize in these fish, demon-
strating the requirement for a functional circulatory
system in this process [15]. Injection into the yolk sac,
however, has complications apparently associated with
poor resealing of the yolk sac membrane which leads to
spillage of the cancer cells or yolk sac contents. The
perivitelline space between the body of the fish and the
yolk sac provides an alternative, which does not suffer
from these associated problems. The technical challenge is
successfully targeting the perivitelline space, and avoiding
injection directly into the circulatory system. For this
reason we examined fish after 12 hours for the presence
of cells in the vasculature and excluded these fish from
the analysis. Since the injection involves large numbers of
fish, excluding those that have been compromised during
the injection process does not have any impact on the
final analysis.
Although zebrafish have been used as a model for
metastasis previously, protocols between different groups
were not consistent in terms of the number of cells
injected, the site of injection, the age of the fish used and
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evaluate this metastasis model more robustly, we have
used a standardized protocol with a variety of different
cancer cells and cell systems. In this report we clearly
demonstrate that metastasis in the zebrafish correlates
with in vitro invasion assays and in one case (DU145 cells,
Figure 3) with metastasis potential in murine models of
metastasis. We observed that metastatic spread in the fish
was achieved as early as 24 hpi, and possibly sooner, and
that the maximum tumor spread was achieved within
48 hours in most cases, without a significant increase over
subsequent days. A reduction in the numbers of cancer
cells, however, occurred when the analysis was extended
to 5 dpi. The metastasis assay, however, if initiated at 2
dpi, can be completed before it is necessary to feed the
fish (4 dpi) and, at least in the cells we tested, do not need
to be followed for more that 2–3 days to evaluate meta-
stasis. In prior studies, the number of cells injected into
the fish varied between 50–2000 [14-17,19-22]. We
observed that injecting too many cells can lead to morta-
lity in our system and, following preliminary evaluation of
the optimal number to demonstrate metastasis, we con-
sistently injected cells ~300 cells per fish.
In many of our studies, the difference in the number
of disseminated cells between the metastatic and non-
metastatic tumors was usually striking. The same was
observed in experimental cell systems where inactivation
of a particular gene led to almost complete loss of inva-
sion or metastasis, e.g. the JAK1 deficient 2C4 cells or
the DU145 WASF3 knockdown cells. In these experi-
ments, however, cells were seen outside the yolk sac
region, which raised the issue of how metastasis is de-
fined? In cell lines such as T47D, LNCAP and HT29,
which are generally considered non-metastatic, our ana-
lysis showed that, even if there were disseminated cells,
in the majority there were usually only between 1–5 cells
in the body of the fish, where 5 cells was the exception.
There are several reasons why small numbers of cells
may appear in the fish body. Firstly, on rare occasions,
the injection procedure could have inadvertently pene-
trated the vasculature and cells were introduced directly,
although we screened all fish 12 hours after injection
and excluded any that already showed cells outside the
yolk sac region to overcome this being a major factor in
the analysis. In practice this was only a very small num-
ber (<2%) for each cohort. It is also possible that cells
defined as non-metastatic, are in fact weakly metastatic,
and so occasional cells will disseminate into the fish.
This is particularly true in experimental systems when,
for example, shRNA knockdown of a particular gene is
not complete, leaving some cells with gene expression
levels above the threshold that will allow metastasis. It is
important to note, however, that in many of our expe-
riments involving apparently non metastatic cells, thepresence of >5 disseminated cells was only seen in a
minority of fish in the cohort. The main criterion for
metastasis, therefore, is the presence of >5 cells in the
majority of fish. In practice, however, the numbers of
metastatic cells throughout the various cohorts for
metastatic cells was far greater than 5 as shown in
Figure 4 (35–55 cells after 48 hours). The number of
disseminated cells becomes particularly important when
defining relative metastatic potential, as seen in the
MCF10A continuum. In this case the overall number of
cells found outside the yolk sac area correlated with the
invasiveness of the cells in vitro. We expect, however,
most metastasis assays will want to determine whether
ablation or overexpression of a gene leads to changes in
metastatic potential, and following the protocol des-
cribed here will facilitate this determination.
Although we were limited by the number of clinical
samples available to us, the demonstration that primary
human cancer cells can survive, grow, and metastasize in
zebrafish provides a very encouraging proof-of-principle
and opens opportunities to evaluate the metastatic poten-
tial in primary cells from biopsies or following surgery,
which can have important advantages for clinical manage-
ment of the patient. Even though it may take 2–3 weeks
to establish the primary cell cultures, the presence
of metastatic cells in a tumor for which there is a well-
differentiated histopathology, could affect the future
screening and management protocol. In addition, the
well- established systems [36-38] for drug screening in
zebrafish, opens up the possibility of identifying thera-
peutics that can target metastasis on a tumor-by-tumor
basis, so providing a personalized approach to individual
tumors.
Conclusions
In summary, we provide a side-by-side critical evaluation
showing that zebrafish can evaluate the metastatic poten-
tial of human cancer cell lines and primary tumors. The
ability to perform these analyses in large cohorts of fish
allow for robust statistical analysis in a short time frame
(24–120 hours) and provides a rapid means of evaluating
whether genetic manipulation of cells, or cell origin,
affects metastasis in vivo. Where it has been investigated,
the metastasis phenotype in fish is identical to that in
rodents with the advantages that individual cells can be
imaged during the metastasis process.
Methods
Cell culture and primary lung cancer cell isolation
Human breast cancer cells (MDA231 and T47D), pros-
tate cancer cells (DU145 and LNCaP), pancreatic ductal
adenocarcinoma cells (AsPC-1 and BxPC3) and colon
cancer cells (SW620 and HT29) were obtained from the
American Type Culture Collection (ATCC, Rockville,
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2C4, the JAK1-deficient U4C and JAK2-deficient γ2A
derivatives were a gift from Dr. Ivo P. Touw (Erasmus
University Medical Center, The Netherlands) and were
cultured in DMEM supplemented with 10% (v/v) fetal
bovine serum (FBS). The normal MCF10A breast epithe-
lial cell line (M-I) and its derivatives M-II, M-III and
M-IV [27,39], were a gift from Dr. Shuang Huang
(Georgia Regents University, USA). The M-III and M-IV
cells were maintained in DMEM/F-12 supplemented with
5% horse serum. The culture medium for the M-I and
M-II was similar but also included 20 ng/ml recombinant
human EGF (R&D Systems, Minneapolis, MN, USA),
0.5 μg/ml hydrocortisone (Sigma-Aldrich, St. Louis, MO,
USA), 10 μg/ml insulin (Sigma-Aldrich) and 100 ng/ml
cholera toxin (Sigma-Aldrich). Primary lung cancer cells
were obtained immediately after resection, disaggregated
with trypsin and cultured in DMEM for 5–10 days.In vitro invasion assay and experimental metastasis
mouse model
To measure cell invasion potential, matrigel invasion
assays were performed as described previously [7,25]
using Transwells (BD biosciences, San Diego, CA, USA)
with 8-μm pore size filters. The invading cells were fixed
in 3.7% paraformaldehyde and stained with 0.5% crystal
violet in 2% ethanol. The lower surface of the filter was
photographed and the invading cells were counted from
six fields at 200× magnification. Each experiment was
performed in triplicate on at least three occasions. For
experimental metastasis, 6-week-old male SCID mice
were injected with 1 × 106 WASF3 knockdown DU145
cells or the knockdown control cells through the lateral
tail vein [9]. Mice were sacrificed 3 months after injec-
tion and the lung tissues were processed for hematoxylin
and eosin (HE) staining. All experimental procedures
were approved by the Animal Care and Use Committee
of Georgia Regents University.Cell preparation and transplantation
For cell labeling, cells were incubated with cell tracker
CM-Dil (Invitrogen, Carlsbad, CA, USA) at a final con-
centration of 2.5 μg/ml for 4 min at 37°C followed by
15 min at 4°C. To remove unincorporated dye, cells
were rinsed twice with phosphate-buffered saline (PBS),
and then resuspended at a higher concentration (5 × 106
cells/ml). Before injection, CM-Dil labeled cells were
assessed for viability using trypan blue exclusion and
only samples in which there was >90% viability were
used. We also evaluated the cells for uniform red stai-
ning and membrane integrity using a Zeiss Axiovert
microscope (Zeiss, Thornwood, NY, USA) before being
transplanted into the fish.Zebrafish husbandry and the metastasis model
Zebrafish were maintained using established temperature
and light cycle conditions as previously described [40,41].
All experimental procedures were approved by the Animal
Care and Use Committee of Georgia Regents University.
The Tg(kdrl:EGFP) transgenic fish line was a gift from Dr.
Daniel Wagner (Department of Biochemistry and Cell
Biology, Rice University, USA). For zebrafish xenotras-
plantation, 48 hpf wild-type AB or Tg(kdrl:EGFP) strains
of transgenic zebrafish embryos were dechorionated and
anaesthetized in 0.3× Danieau's solution containing
phenythiourea (PTU, Sigma-Aldrich) and 0.04 mg/ml
tricaine (Sigma-Aldrich) before human cell injection.
Approximately 300 CM-Dil labeled human cells were
injected into the perivitelline cavity of each embryo, and
zebrafish were maintained in 0.3× Danieau's solution
containing PTU for 1 h at 28°C. After confirmation of a
visible cell mass at the injection site, zebrafish were trans-
ferred to an incubator and maintained at 34°C.
Confocal imaging
Living zebrafish embryos were anesthetized using
0.04 mg/ml tricaine and were then embedded in a lateral
orientation in 0.5% agarose. Serial sections were captured
using an Olympus FLUOVIEW™ FV1000 laser scanning
confocal microscope (Olympus, Tokyo, Japan) and 2.5 μm
z-step intervals. Low magnification (×4 objective) was
used to provide an overview of the tumor cell metastasis
pattern throughout the fish, and higher magnification
(×20 objective) was used to define the precise localization
of metastatic cells and foci within the zebrafish. Z-stack
images were processed using ImageJ/Fiji as previously des-
cribed [40,42].
Automated cell counting and statistical analysis
The custom Fiji (ImageJ2) software package [26] was
used for automated cell counting. Briefly, a 190–255 in-
tensity threshold was set to select cells and the ‘analyze’
particle tool was used with default selection of cell size
and cell shape during counting. A Fiji macro was gene-
rated using the ‘record’ function to streamline analyses
and remove bias. To count the metastatic cell number in
the tail, the fish tails were selected for cell counts using
the polygon selection tool. A P-value of 0.05 or less was
considered to be statistically significant and determined
by the Student’s t-test. Values of three or more expe-
riments were given as mean ± SEM.
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